• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

2 de May de 2008
Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2008-05-02 10:00:002008-05-02 10:00:00Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

19 de March de 2008
Mol Cancer Ther. 2008 Mar;7(3):638-47. doi: 10.1158/1535-7163.MCT-07-2122.ABSTRACTGemcitabine…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2008-03-19 10:00:002008-03-19 10:00:00Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

19 de March de 2008
Mol Cancer Ther. 2008 Mar;7(3):638-47. doi: 10.1158/1535-7163.MCT-07-2122.ABSTRACTGemcitabine…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2008-03-19 10:00:002008-03-19 10:00:00Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

BMP-2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells

6 de February de 2008
J Cell Physiol. 2008 Jul;216(1):144-52. doi: 10.1002/jcp.21389.ABSTRACTBone…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2008-02-06 11:00:002008-02-06 11:00:00BMP-2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells

Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma

5 de January de 2008
Clin Infect Dis. 2008 Feb 1;46(3):440-2. doi: 10.1086/524695.ABSTRACTWe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2008-01-05 11:00:002008-01-05 11:00:00Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma

Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients

24 de October de 2007
Am J Clin Pathol. 2007 Nov;128(5):875-82. doi: 10.1309/2YGD1P0QCVCWBLDX.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2007-10-24 10:00:002007-10-24 10:00:00Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients

Autologous and allogeneic stem cell transplantation in Hodgkin’s lymphoma

3 de October de 2007
Hematol Oncol Clin North Am. 2007 Oct;21(5):943-60. doi: 10.1016/j.hoc.2007.07.008.ABSTRACTNewly…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2007-10-03 10:00:002007-10-03 10:00:00Autologous and allogeneic stem cell transplantation in Hodgkin’s lymphoma

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

15 de September de 2007
Br J Haematol. 2007 Oct;139(1):70-80. doi: 10.1111/j.1365-2141.2007.06759.x.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2007-09-15 10:00:002007-09-15 10:00:00Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway

4 de September de 2007
Biochem Pharmacol. 2007 Nov 1;74(9):1340-9. doi: 10.1016/j.bcp.2007.07.016.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2007-09-04 10:00:002007-09-04 10:00:00The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway

Transfrontal three-dimensional visualization of midline cerebral structures

3 de July de 2007
Ultrasound Obstet Gynecol. 2007 Aug;30(2):162-8. doi: 10.1002/uog.4073.ABSTRACTOBJECTIVE:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2007-07-03 10:00:002007-07-03 10:00:00Transfrontal three-dimensional visualization of midline cerebral structures

Adult T-cell leukemia/lymphoma with a mixed CD4+ and CD8+ phenotype and indolent course

15 de June de 2007
J Clin Oncol. 2007 Jun 10;25(17):2480-2. doi: 10.1200/JCO.2007.11.3043.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2007-06-15 10:00:002007-06-15 10:00:00Adult T-cell leukemia/lymphoma with a mixed CD4+ and CD8+ phenotype and indolent course

Metronomic chemotherapy: an antiangiogenic scheduling

3 de March de 2007
Clin Transl Oncol. 2007 Feb;9(2):93-8. doi: 10.1007/s12094-007-0018-3.ABSTRACTConventional…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2007-03-03 11:00:002007-03-03 11:00:00Metronomic chemotherapy: an antiangiogenic scheduling
Page 81 of 87«‹7980818283›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}